Meeting
2016 ASCO Annual Meeting
Anti-PD-1 tolerance after severe toxicity with ipilimumab therapy in metastatic melanoma patients.
Authors
Angelique Brunot
Comprehensive Cancer Center Eugene Marquis, Rennes, France
Angelique Brunot , Geraldine Jeudy , Mathieu Tas , Bernard Guillot , Nora Kramkimel , Laurent Mortier , Sandrine Mansard , Celeste Lebbe , Astrid Blom , Yannick Le Corre , Henri Montaudie , Sorilla Prey , Boris Campillo-Gimenez , Thierry Lesimple
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9551)
DOI
10.1200/JCO.2016.34.15_suppl.9551
Abstract #
9551
Poster Bd #
156
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Autoimmune toxicities with anti-PD-1 treatment of metastatic melanoma in predominantly older patients: A single institutional experience.
First Author: Harsh V Parmar
Poster
2016 ASCO Annual Meeting
Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
First Author: Claire Frances Friedman
Poster
2024 ASCO Annual Meeting
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
First Author: Charlee Nardin
Poster
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
First Author: Thierry Landre